ArticleFrontiers in medicine2025
ATG16L1 promotes cell migration and invasion in high glucose-induced retinal capillary endothelial cells.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Diabetic retinopathy (DR), a common chronic complication of diabetes, often results in irreversible visual dysfunction. This study investigated the mechanisms underlying the expression of ATG16L1, a potential biomarker of DR. Methods: We investigated the role of ATG16L1 in high glucose (HG)-induced retinal capillary endothelial cells (RCECs). Rat RCECs were cultured in normal glucose (NG) or HG medium with or without ATG16L1 transfection. Results: The mRNA and protein expression levels of ATG16L1 were significantly upregulated in RCECs exposed to HG medium. The migration ability and invasion rate of RCECs were significantly higher in the HG group than in the NG group but decreased markedly after transfection with ATG16L1 siRNA, compared with those in the control group ( Conclusion: ATG16L1 might be involved in the development of DR by promoting the migration of RCECs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.